478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study

Antonella Palazzo ,A Lai,A Fontana,F Pantaleo,E Di Monte,L Rinaldi,Nadia Bianco ,Francesco Giotta ,Angela Toss ,Alessandra Gennari ,Marta Perachino ,Patrizia Vici ,Laura De Marchis ,Gian Paolo Spinelli ,Nicoletta Staropoli ,Marta Nerone ,Matteo Lambertini ,Rossella Graffeo ,Laura Cortesi ,Emilio Bria

doi:10.1016/j.annonc.2023.09.654

478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study

Antonella Palazzo , A Lai + Show 18 more

https://doi.org/10.1016/j.annonc.2023.09.654

Copy DOI

Journal: Annals of Oncology

Publication Date: Oct 1, 2023

Affiliation: Agostino Gemelli University Polyclinic, Azienda Ospedaliera Universitaria Pisana, Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Tumori Bari, Polytechnic University of Bari, European Institute of Oncology, Policlinico di Modena, Azienda Ospedaliera Ospedale Maggiore, Ospedale Policlinico San Martino, Sapienza University of Rome, Magna Graecia University, Ospedale Regionale di Bellinzona e Valli, Ospedale regionale di Lugano, Università Cattolica del Sacro Cuore

#Pathogenetic Variants #HER2-negative Metastatic Breast Cancer Patients + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.